Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference
02 Enero 2019 - 6:00AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta therapeutics
to treat serious and rare diseases, today announced that Habib
Dable, President and Chief Executive Officer, will present an
overview of the company along with its upcoming corporate
priorities at the 37th Annual J.P. Morgan Healthcare Conference on
Monday, January 7, 2019 at 2:00 p.m. PST / 5:00 p.m. EST in San
Francisco, California.
In addition, the Company will webcast the question and answer
breakout session immediately following its presentation at 2:30
p.m. PST / 5:30 p.m. EST.
The live webcast of the presentation and breakout session can be
accessed on the Investors page of the Company's website at
www.acceleronpharma.com. A replay of the webcast will be available
approximately two hours after the event on the Acceleron
website.
About Acceleron
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical
company dedicated to the discovery, development, and
commercialization of therapeutics to treat serious and rare
diseases. The Company's leadership in the understanding of TGF-beta
biology and protein engineering generates innovative compounds that
engage the body's ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2
pulmonary program with sotatercept in pulmonary arterial
hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190102005112/en/
Todd James, IRC, 617-649-9393Vice President, Investor Relations
and Corporate CommunicationsorMedia:Matt Fearer,
617-301-9557Director, Corporate Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024